1. Arming T cells with C-X-C-motive receptor 6 enables adoptive T cell therapy of pancreatic cancer. (March 2019) Authors: Lesch, S.; Blumenberg, V.; Stoiber, S.; Ogonek, J.; Cadilha, B.; Dantes, Z.; Rataj, F.; Dorman, K.; Lutz, J.; Karches, C.; Heise, C.; Grassmann, S.; Megens, R.; Ruehland, S.; Di Pilato, M.; Pruessmann, J.; Ormanns, S.; Reischer, A.; Duewell, P.; Schnurr, M. Journal: European journal of cancer Issue: Volume 110(2019)Supplement 1 Page Start: S25 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. EXTRANODAL DISEASE IS ASSOCIATED WITH SHORTER PROGRESSION‐FREE SURVIVAL AFTER CD19‐CAR T‐CELL THERAPY FOR RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA. (17th June 2021) Authors: Bücklein, V.; Blumenberg, V.; Ackermann, J.; Frölich, L.; Winkelmann, M.; Schmidt, C.; Rejeski, K.; Ruzicka, M.; Müller, N.; von Baumgarten, L.; Schöberl, F.; Hildebrandt, M.; Humpe, A.; Kunz, W.; Hoster, E.; von Bergwelt, M.; Subklewe, M. Journal: Hematological oncology Issue: Volume 39(2021)Supplement 2 Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P1438: PROCALCITONIN IS ELEVATED IN SEVERE INFECTIONS AFTER CD19 CAR-T IN R/R B-NHL AND ENABLES DISCRIMINATION OF EARLY INFECTIONS FROM CRS – PARTICULARLY IN COMBINATION WITH THE CAR-HEMATOTOX SCORE. (23rd June 2022) Authors: Rejeski, K.; Blumenberg, V.; Hildebrand, F.; Frölich, L.; Karschnia, P.; Dreyling, M.; von Bergwelt-Baildon, M.; Schmidt, C.; Subklewe, M.; Bücklein, V. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1321 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P1445: MYTCELL®: AN INTERACTIVE SMARTPHONE APPLICATION FOR CARS AND BITES INCREASES GUIDELINE ACCESSIBILITY AND REDUCES TIME TO APPLY EVIDENCE-BASED PATIENT CARE. (23rd June 2022) Authors: Blumenberg, V.; Siegmund, L.; Frölich, L.; Rejeski, K.; Warm, M.; Hildebrand, F.; Schmidt, C.; von Bergwelt, M.; Bücklein, V.; Subklewe, M. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1328 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P1447: INFERIOR OUTCOMES OF EU VS. US PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA AFTER CD19 CAR T-CELL THERAPY ARE IMPACTED BY BASELINE RISK FACTORS AND CAR PRODUCT CHOICE. (23rd June 2022) Authors: Bücklein, V.; Perez, A.; Iacoboni, G.; Rejeski, K.; Holtick, U.; Penack, O.; Kharboutli, S.; Blumenberg, V.; Ackermann, J.; Frölich, L.; Johnson, G.; Patel, K.; Arciola, B.; Schmidt, C.; Albanyan, O.; Gödel, P.; Hoster, E.; Bullinger, L.; Mackensen, A.; Locke, F. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1330 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. P1458: PATTERNS OF LONG-TERM HEMATOPOIETIC RECOVERY IMPACT SURVIVAL OUTCOMES AFTER CD19-DIRECTED CAR T-CELL THERAPY FOR R/R LBCL. (23rd June 2022) Authors: Rejeski, K.; Albanyan, O.; Iacoboni, G.; Bücklein, V.; Blumenberg, V.; Penack, O.; Bethge, W.; Völkl, S.; Perez, A.; Carpio, C.; Schmidt, C.; Müller, N.; Reid, K.; Faramand, R.; Davila, M.; Bullinger, L.; Locke, F.; von Bergwelt-Baildon, M.; Mackensen, A.; Barba, P. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1340 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. PB2210: FAVORABLE OUTCOME AFTER SECOND CD19 CAR T INFUSION OF AN IDENTICAL PRODUCT: HOST ENVIRONMENT AND DISEASE CHARACTERISTICS DETERMINE THE OUTCOME OF TREATMENT. (23rd June 2022) Authors: Frölich, L.; Blumenberg, V.; Rejeski, K.; Schmidt, C.; Winkelmann, M.; Schöberl, F.; von Baumgarten, L.; Kunz, W.; Bücklein, V.; Subklewe, M. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 2080 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗